First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

This is the first combination study of a BCMA- and GPRC5D-targeted bispecific antibody. This study evaluated the safety of a regimen combination of tec, the first BCMA-directed bispecific antibody approved for the treatment of triple-class exposed relapsed/refractory multiple myeloma, and tal, a bispecific antibody targeting the novel myeloma antigen GPRC5D. The study also aimed to identify a recommended phase 2 regimen for the combination.